Harold Giles, MD
Nephrology · Homewood, ALNPI 1811945454
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,600 of the $17,721 with a category attached, or 82.4%. 10 manufacturers reported payments, led by Nxstage Medical, Inc. at 55.6% of the total. Reporting peaked in 2022 at $8,369 and has fallen 99.7% since, to $26 in 2025.
Across 46 payments — averaging $385.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nxstage Medical, Inc.$10K
- Fresenius USA Marketing, Inc.$7K
- Akebia Therapeutics Inc$286
- Amgen$142
- AstraZeneca$99
- Travere Therapeutics, Inc.$22
- plus $70 from 4 others
What the payments were for
- Consulting fees$14,60082%
- Travel & lodging$1,5419%
- Food & beverage$1,5609%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nxstage Medical, Inc. | 20 | $9,849 |
| Fresenius USA Marketing, Inc. | 6 | $7,252 |
| Akebia Therapeutics Inc | 11 | $286 |
| Amgen(2 entities) | 2 | $142 |
| AstraZeneca(2 entities) | 2 | $99 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Sanofi | 1 | $18 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$6,110
- System One$3,328
- Velphoro$2,100
- Parsabiv$116
- LIBERTY SELECT CYCLER$110
How this compares
$17,721 in reported general payments places this provider in the 85th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 38 | $122,053 |
| FarxigaDapagliflozin Propanediol | 170 | $113,602 |
| VelphoroSucroferric Oxyhydroxide | 14 | $39,286 |
| JardianceEmpagliflozin | 21 | $17,975 |
| Sevelamer Carbonate | 96 | $15,953 |
| KerendiaFinerenone | 11 | $6,997 |
| Calcium Acetate | 75 | $6,729 |
| Potassium Chloride | 220 | $6,358 |
| Furosemide | 250 | $4,828 |
| Nystatin | 111 | $2,930 |
| Gentamicin Sulfate | 86 | $2,680 |
| Calcitriol | 132 | $2,628 |
| Telmisartan | 49 | $1,728 |
| Clonidine | 11 | $917 |
| Cinacalcet Hcl | 14 | $906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $286 | $122,05338 claims |
| AstraZenecaFarxiga | $99 | $113,602170 claims |
| Fresenius USA Marketing, Inc.Velphoro | $7,252 | $39,28614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 nephrology providers in Alabama.
Other nephrology in Homewood
- Thomas OzbirnHomewood$133K
- Jeffrey GlazeHomewood$98K
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.